BlackRock
MIRM icon

BlackRock’s Mirum Pharmaceuticals MIRM Stock Holding History

BlackRock’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$514M Buy
4,390,063
+543,533
+14% +$54.6M 0.01% 1194
2026
Q1 		$355M Buy
3,846,530
+201,244
+6% +$18.9M 0.01% 1327
2025
Q4 		$288M Buy
3,645,286
+42,852
+1% +$3.08M ﹤0.01% 1460
2025
Q3 		$264M Buy
3,602,434
+25,343
+0.7% +$1.61M ﹤0.01% 1499
2025
Q2 		$182M Buy
3,577,091
+237,534
+7% +$10.6M ﹤0.01% 1676
2025
Q1 		$150M Sell
3,339,557
-95,071
-3% -$4.48M ﹤0.01% 1751
2024
Q4 		$142M Buy
3,434,628
+66,471
+2% +$2.77M ﹤0.01% 1867
2024
Q3 		$131M Buy
3,368,157
+130,108
+4% +$5.19M ﹤0.01% 1924
2024
Q2 		$111M Buy
3,238,049
+785,776
+32% +$20.6M ﹤0.01% 1963
2024
Q1 		$61.6M Sell
2,452,273
-9,477
-0.4% -$261K ﹤0.01% 2320
2023
Q4 		$72.7M Buy
2,461,750
+348,341
+16% +$10.5M ﹤0.01% 2267
2023
Q3 		$66.8M Buy
2,113,409
+83,034
+4% +$2.27M ﹤0.01% 2231
2023
Q2 		$52.5M Buy
2,030,375
+320,549
+19% +$8.53M ﹤0.01% 2450
2023
Q1 		$41.1M Sell
1,709,826
-426,851
-20% -$9.73M ﹤0.01% 2582
2022
Q4 		$41.7M Buy
2,136,677
+387,328
+22% +$7.66M ﹤0.01% 2591
2022
Q3 		$36.8M Buy
1,749,349
+353,337
+25% +$8.51M ﹤0.01% 2678
2022
Q2 		$27.2M Buy
1,396,012
+613,182
+78% +$14.5M ﹤0.01% 2911
2022
Q1 		$17.2M Buy
782,830
+10,732
+1% +$219K ﹤0.01% 3268
2021
Q4 		$12.3M Buy
772,098
+161,533
+26% +$2.51M ﹤0.01% 3549
2021
Q3 		$12.2M Buy
610,565
+2,831
+0.5% +$46K ﹤0.01% 3586
2021
Q2 		$10.5M Sell
607,734
-153,105
-20% -$2.74M ﹤0.01% 3621
2021
Q1 		$15.1M Buy
760,839
+205,950
+37% +$3.94M ﹤0.01% 3339
2020
Q4 		$9.69M Buy
554,889
+132,920
+31% +$2.61M ﹤0.01% 3378
2020
Q3 		$8.13M Sell
421,969
-3,569
-0.8% -$76.6K ﹤0.01% 3339
2020
Q2 		$8.28M Buy
425,538
+168,803
+66% +$2.82M ﹤0.01% 3291
2020
Q1 		$3.59M Buy
256,735
+75,566
+42% +$1.24M ﹤0.01% 3475
2019
Q4 		$4.44M Buy
181,169
+146,114
+417% +$1.56M ﹤0.01% 3542
2019
Q3 		$352K Buy
+35,055
New +$430K ﹤0.01% 4231

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock's MIRM Position: Q2 2026 in Review

BlackRock increased its Mirum Pharmaceuticals (MIRM) stake by 14% in Q2 2026, buying an estimated $54.6M and bringing the position to 4,390,063 shares worth $514M. The position accounts for 0.01% of the portfolio, ranked #1194.

BlackRock first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • BlackRock held 4,390,063 shares of Mirum Pharmaceuticals worth $514M as of Q2 2026.
  • BlackRock bought 543,533 Mirum Pharmaceuticals shares in Q2 2026, an estimated $54.6M.
  • Mirum Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q2 2026, its #1194 holding.
  • BlackRock first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.